ImmunitoAI builds lab to test AI-designed antibodies in-house

ImmunitoAI has brought antibody testing in-house, combining an AI design platform with its own laboratory to validate candidates for specific disease targets. The startup, which was recently covered by another outlet, now designs and tests antibodies without relying on external partners.

This move reflects a broader trend in AI-driven drug discovery, where startups are tightening the loop between computational prediction and experimental validation. Basecamp Research, which secured $140 million last month, follows a similar model, though ImmunitoAI’s focus on antibodies—rather than small molecules or proteins—sets it apart in a crowded field.

The integration of wet-lab capabilities could reduce the time and cost of early-stage drug development, a persistent bottleneck in biotech. Yet it also raises questions about scalability: maintaining a lab requires capital and operational expertise, and few AI drug discovery startups have successfully brought candidates to clinical trials. The startup’s approach will test whether vertical integration can accelerate the path from target to lead compound.

For now, the company remains under the radar. Unlike Basecamp Research, it hasn’t disclosed funding or partnerships, leaving its traction and runway unclear. Observers will watch whether its in-house testing yields validated antibodies—and whether that justifies the investment in physical infrastructure.

Sources: yourstory.com